Skip to content

Pulse Therapeutics is proud to announce its merger with ICHOR Vascular and the subsequent creation of Euphrates Vascular. For more information, contact CEO Sean Morris.


Euphrates’ Ichor Featured in EV Today’s Thrombectomy Buyer’s Guide

Euphrates Vascular’s ICHOR Percutaneous Reperfusion System is included in EV Today’s Device Guide for Mechanical Thrombectomy/Thrombolysis. This helpful buyer’s guide includes: Sheath compatibility Guidewire compatibility Working length Mode of operation US FDA indicated use View EV Today’s Thrombectomy Guide

Read More

Euphrates Vascular Featured in Endovascular Today

Euphrates Vascular was recently featured in Endovascular Today. The article, “Euphrates Vascular’s Ichor Reperfusion System Cleared by FDA,” discusses how the newly-approved Ichor system targets vascular occlusions by eliminating the need for surgery or drug therapies. Highlights: Euphrates Vascular received FDA 510(k) clearance for the sale of its Ichor percutaneous reperfusion system, which is designed…

Read More
ICHOR Percutaneous Reperfusion System

Euphrates Vascular announces FDA clearance of the ICHOR Reperfusion System 

St. Louis, Missouri – Euphrates Vascular (, a company focused on the treatment of vascular occlusions, recently received 510(k) clearance for sale of its ICHOR Percutaneous Reperfusion System. ICHOR is a Percutaneous Reperfusion System designed to treat organized thrombus and embolic events in the peripheral vasculature. ICHOR is a “one size fits all” system that…

Read More

Pulse Therapeutics and ICHOR Vascular Merge to Form Euphrates Vascular

Company aimed at becoming a leader in the treatment of vascular occlusions St. Louis, Missouri – Euphrates Vascular ( is a medical device company created via the merger between Pulse Therapeutics and ICHOR Vascular. Bringing together technological synergies and experienced team members, the Euphrates Vascular (EV) vision is to become the leader in the treatment…

Read More

ICHOR Featured in MedTech Strategist

ICHOR was recently featured in MedTech Strategist in the “Start ups to Watch” by senior writer Mary Stuart. The two-page article discusses how ICHOR Vascular is bringing the benefits of a minimally invasive procedure to Arterial Embolectomy. Acute limb ischemia, the sudden occlusion of a peripheral artery by clot or other embolic material, is a life-…

Read More

Pulse Therapeutics Supports Stroke Awareness Month in May

Stroke is Preventable in 80% of Cases Recognizing Warning Signs, By Adopting Healthy Lifestyle The devastating impact of stroke, the nation’s fourth deadliest disease, is undeniable. Stroke impacts 795,000 people each year, according to the American Heart Association/American Stroke Association (AHA/ASA). It costs patients $33 billion annually and leaves survivors temporarily to permanently paralyzed or otherwise…

Read More

Pulse Therapeutics’ MED System Featured by Horizon Scanning Research & Intelligence Centre

The Horizon Scanning Research & Intelligence Centre (HSRIC), a research programme within the National Institute for Health Research (NIHR), has published a technology alert about the Magnetically-Enhanced Diffusion (MED) System™ in development by Pulse Therapeutics, Inc. The alert shares how the MED System is designed to improve the delivery of thrombolytic therapy in people who…

Read More

Pulse Therapeutics Featured in Med Device Online

Companies To Watch: Pulse Therapeutics By Jim Pomager in Med Device Online Magnetically spinning nanoscale particles may overcome a major barrier to effective stroke treatment — helping clot-busting drugs traverse stopped arteries. Snapshot Pulse Therapeutics has developed a mechanical thrombolysis technology that accelerates the delivery of clot-busting drugs to a clogged artery. The Magnetically Enhanced…

Read More

Pulse CEO Featured in St. Louis Business Journal

Pulse Therapeutics, Inc. is no stranger to media coverage. Since its founding in 2008, local, state and national publications have followed the developments of the pioneering medical developer. Most coverage has concerned its flagship MED System™ and the work of founder Duke Creighton. In June 2014, reporter Brian Feldt of the St. Louis Business Journal…

Read More

TV coverage on Pulse Therapeutics’ MED System

Pulse Therapeutics’ MED System was featured on an Australian television health report about its trials in Melbourne. A transcript of the video: Melbourne patients trial new technology to combat stokes. The therapy speeds up the delivery of drugs to the brain to prevent permanent damage. Doctors have only a small window in which to give…

Read More